Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises FSN Capital and Seriline in connection with the add-on acquisition of Areff Systems
Mandate

Vinge advises FSN Capital and Seriline in connection with the add-on acquisition of Areff Systems

May 24, 2022 Employment and Benefits IT, Telecommunications and Outsourcing M&A Intellectual Property

Vinge advises FSN Capital and Seriline in connection with the acquisition of Areff Systems AB from its founders. The founders remain in the merged company and has reinvested a significant proportion of the purchase price in the group.

At the end of February 2022, the private equity firm FSN Capital acquired a majority stake in Seriline with the ambition of consolidating the market for physical and digital identity and access control. The acquisition of Seriline is now followed up with the acquisition of Areff Systems, where FSN Capital accounts for a majority of the financing. Areff Systems works with security and identification solutions and currently has 18 employees. The acquisition of Areff Systems will increase Seriline’s turnover with almost 50 percent to around SEK 150 million for 2022.

Vinge’s team mainly consisted of Johan Winnerblad, Maria Dahlin Kolvik, Eléonore Friberg and Ebba Nyberg (M&A), Mathilda Persson (IT), Sara Strandberg (Employment) and Axel Lennartsson (IPR).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025